Valuation dashboard for Profound Medical Corp. (PROF) with P/E N/A, P/B 4.06, EV/EBITDA -5.25 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland.
Analysis Summary
Profound Medical Corp. reported revenue of $16.4M in the most recent fiscal year, growing at a 5-year CAGR of 17.5%.
Trailing-twelve-month margins: gross margin 71.7%, operating margin -184.3%, net margin -170.9%.
At the current price of $5.89, PROF has negative trailing earnings (P/E not meaningful) and an ROE of -62.45%. Market capitalisation stands at $214M.
Balance sheet quality for PROF: current ratio of 12.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 4.06 |
| EV / EBITDA | -5.25 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-21.86 |
| vs Current Price | -471.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PROF | Profound Medical Corp. | $212M | 4.06 | -62.5% | |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 29.27 | 4.55 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $66.5B | 48.91 | 5.86 | 11.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price
| Price | $5.89 |
| Market Cap | $214M |
| Exchange | NASDAQ |
| Country | CA |
Profitability
| Return on Equity | -62.45% |
| Return on Invested Capital | -60.49% |
| Return on Assets | -52.05% |
| Gross Margin | 71.73% |
| Operating Margin | -184.35% |
| Net Margin | -170.92% |
Related companies: ARMP · AVR · CATX · LNSR · MXCT · NNOX · OWLT
Explore sector: Healthcare · Medical - Devices
More sections of PROF: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks